Prokarium snags $21m Series B

London-based Prokarium, a developer of novel immunotherapies and vaccines based on its engineered microbial platform, has raised $21 million in Series B funding.

London-based Prokarium, a developer of novel immunotherapies and vaccines based on its engineered microbial platform, has raised $21 million in Series B funding. Korea Investment Partners led the round.

Source: Press Release